Relevant bibliographies by topics / 45.8 to 50(Category III)

Contents

  1. Journal articles
  2. Conference papers

Academic literature on the topic '45.8 to 50(Category III)'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '45.8 to 50(Category III).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "45.8 to 50(Category III)"

1

Fornari, Gianni, Elisa Artusio, Lorenza Mairone, et al. "Paclitaxel and Carboplatin in Neo-Adjuvant and Concomitant Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma." Tumori Journal 88, no. 6 (2002): 489–94. http://dx.doi.org/10.1177/030089160208800611.

Full text
Abstract:
Aim and background To evaluate feasibility of neoadjuvant chemotherapy (NA-CT) followed by CT + radiotherapy (RT) in locally advanced or unresectable head and neck squamous cell carcinoma (HNSCC). Methods 22 HNSCC patients were enrolled (18 males, 4 females; median age, 59.5 years; median ECOG PS, 1). Sites of disease: oral cavity, 18.2%; oropharynx, 40.9%; hypopharynx, 18.2%; larynx, 4.6%, multiple sites, 18.2%. T (tumor) category: T2, 13.6%; T3, 31.8%;T4, 54.5%. N (nodes) category: N0, 9.1%; N1, 18.1%; N2, 40.9%; N3, 31.8%. Stage: III, 4.6%; IVA, 63.6%; IVB, 31.8%. Induction carboplatin (AUC
APA, Harvard, Vancouver, ISO, and other styles
2

Pruitt, Margaret, Rajesh Naidu Janapala, and Faysal Haroun. "Patterns of lung cancer in people living with human immunodeficiency virus (HIV): A retrospective, single-center study in Washington, D.C." Journal of Clinical Oncology 39, no. 15_suppl (2021): e21154-e21154. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e21154.

Full text
Abstract:
e21154 Background: Lung cancer is the leading cause of cancer death and the most common non-acquired immune deficiency syndrome defining malignancy in people living with HIV (PLWH). Disparities in outcomes have been observed despite lung cancer mortality reportedly decreasing in the general population over the last decade due to lower rates of smoking and the advent of novel therapies. To better understand the current trend in lung cancer in PLWH, we explored demographic characteristics, comorbidities, and lung cancer pathology and molecular data in this population. Methods: A retrospective se
APA, Harvard, Vancouver, ISO, and other styles
3

Miletic, Marija, Razia Aslam, Catey Bunce, et al. "Therapeutic approaches and outcomes in patients aged 50+ with germ cell tumours." Journal of Clinical Oncology 43, no. 5_suppl (2025): 636. https://doi.org/10.1200/jco.2025.43.5_suppl.636.

Full text
Abstract:
636 Background: Testicular germ cell tumours (GCT) are the most common malignancy in young men, mainly in their 30s. While multimodal treatment leads to excellent survival in younger patients (pts), its incidence is rising in men over 50, who often have comorbidities and higher risks of chemotherapy (ChT) toxicity. Limited data on outcomes in this group highlights the need for more research. Methods: We conducted a retrospective single centre study, analysing pts diagnosed with GCT aged 50 years or older between 2014 -2023. Results: 142 pts were analysed, median age of 57 years (range 50–83).
APA, Harvard, Vancouver, ISO, and other styles
4

Lai-Kwon, Julia Elizabeth, Michael Jefford, Ashkan Mehrnejad, et al. "Financial toxicity and employment outcomes in people with melanoma receiving adjuvant therapies." Journal of Clinical Oncology 43, no. 16_suppl (2025): 9577. https://doi.org/10.1200/jco.2025.43.16_suppl.9577.

Full text
Abstract:
9577 Background: One year ofadjuvant anti-programmed cell death protein-1 (anti-PD1) or dabrafenib-trametinib are standards of care for patients (pts) with resected stage III-IV melanoma. The impact of adjuvant therapy on a pt’s employment, income, and level of financial toxicity are unknown. We examined these outcomes up to 2 years post initiation of adjuvant therapy. Methods: A prospective, longitudinal study of pts with resected stage IIB-IV melanoma receiving adjuvant anti-PD1 or dabrafenib-trametinib at an Australian comprehensive cancer center. Two customized employment surveys assessed
APA, Harvard, Vancouver, ISO, and other styles
5

Abouyabis, Abeer N., MaryJo Lechowicz, Karen Mann, et al. "Benefits of CHOP-14 Followed by Transplantation in Patients with Peripheral T-Cell Lymphoma." Blood 108, no. 11 (2006): 4689. http://dx.doi.org/10.1182/blood.v108.11.4689.4689.

Full text
Abstract:
Abstract Background: Compared to B-cell lymphomas, peripheral T-cell non-Hodgkin lymphomas (PTCL) represent a subtype that more frequently involve extranodal sites and worse relapse free survival (RFS) and overall survival (OS) with and without risk stratification by the international prognostic index (IPI). Moreover, while traditional anthracycline containing regimens can induce complete remission (CR), they have not significantly improved long-term outcomes for patients (pts) with PTCL and resulted in 5-year OS and failure-free survival of 26% and 20%, respectively. We examined the pathologi
APA, Harvard, Vancouver, ISO, and other styles
6

Gisslinger, Heinz, Veronika Buxhofer-Ausch, Josef Thaler, et al. "Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study." Blood 122, no. 21 (2013): 4046. http://dx.doi.org/10.1182/blood.v122.21.4046.4046.

Full text
Abstract:
Abstract Background AOP2014/P1101 is a novel, investigational mono-pegylated proline-interferon alpha-2b. In contrast to other pegylated IFNs, AOP2014/P1101 consists of one predominant isoform. AOP2014/P1101 has Orphan Drug Designation in EU and USA for treatment of patients with PV. Study design Long term efficacy and safety data are being collected in the follow-up extension stage of the study (collecting the data of both Phase I and Phase II portions of the study), after the maximum tolerated dose (MTD) of AOP2014, administered subcutaneously every 14 days, has been defined earlier. Patient
APA, Harvard, Vancouver, ISO, and other styles
7

Khurana, Arushi, Raphael Mwangi, James R. Cerhan, et al. "Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications." Blood 142, Supplement 1 (2023): 67. http://dx.doi.org/10.1182/blood-2023-190316.

Full text
Abstract:
Background: High Grade B cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements(R) was introduced as an entity in 2016 by the WHO revised 4 th edition. In 2022, both the WHO 5 th edition (beta version) and the International Consensus Classification (ICC) separated DHL- BCL2 (+/- BCL6-R)from DHL- BCL6 given differences in biology . However, while the ICC has maintainedDHL- BCL6 as a provisional entity, the WHO has removed the category, thus removing the requirement to FISH for BCL6-R in this setting. Clinical data on DHL- BCL6 is much more limited, as these cases represent only 10-20
APA, Harvard, Vancouver, ISO, and other styles
8

Astibia Mahillo, Beatriz, María-Jesús Blanchard, Miguel Piris Villaespesa, et al. "Clinical, Biological and Prognostic Characterization of Multiple Myeloma According to the Presence of Circulating Plasma Cells." Blood 144, Supplement 1 (2024): 3349. https://doi.org/10.1182/blood-2024-210589.

Full text
Abstract:
Introduction: According to the updated IMWG consensus definition patients with symptomatic multiple myeloma (MM) presenting with ≥5% circulating plasma cells (cPC) by cytomorphology should be considered as having plasma cell leukemia (PCL). It is a matter of debate whether patients with cPC <5% are associated with an adverse prognosis. The objective of this study is to characterize and evaluate the prognosis of MM according to the level of cPC. Methods: Single-center retrospective study of patients diagnosed with symptomatic MM between 2019-2022 (N=77). A blinded review of blood smears
APA, Harvard, Vancouver, ISO, and other styles
9

Hoelzer, Dieter, Nicola Goekbuget, Joachim Beck, et al. "Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL)." Blood 104, no. 11 (2004): 2732. http://dx.doi.org/10.1182/blood.v104.11.2732.2732.

Full text
Abstract:
Abstract Despite the major peak of ALL in childhood the incidence also increases in the elderly beyond 50 yrs. Outcome of these elderly ALL pts is very poor. In a survey including 12 studies with 370 pts (50–88 yrs) the mean CR rate was 50% and the rate of continuous CR (CCR) 13%. Also in a first prospective pilot study of the German Multicenter Study Group for Adult ALL (GMALL) for elderly ALL pts > 65 yrs with a moderate intensive chemotherapy regimen (Blood, 96(11): 3104a, 2000) the results in 94 pts were poor with a CR rate of 48% and a survival (OS) <10%. Therefore in 2003 t
APA, Harvard, Vancouver, ISO, and other styles
10

Mark, Tomer M., Abbe Schickner, John N. Allan, et al. "Car-Bird [Carfilzomib, Clarithromycin(Biaxin®), Lenalidomide/(Revlimid®), Dexamethasone) for Newly-Diagnosed Multiple Myeloma." Blood 124, no. 21 (2014): 4761. http://dx.doi.org/10.1182/blood.v124.21.4761.4761.

Full text
Abstract:
Abstract Background: Carfilzomib (Cfz), lenalidomide, and dexamethasone synergize to provide an impressive overall response rate (ORR) in upfront treatment of multiple myeloma (MM) (Jakubowiak et al 2012). The ORR to Cfz+dexamethasone (Cfz-Dex) as first-line therapy is unknown. We hypothesized that sequential treatment with Cfz-dex and BiRD would improve provide similar ORR and improve tolerability. A protocol of Cfz-Dex, consolidation with BiRd (Clarithromycin(Biaxin¨), Lenalidomide/(Revlimid¨), dexamethasone), and lenalidomide maintenance (Len) was conducted to evaluate ORR and safety as ind
APA, Harvard, Vancouver, ISO, and other styles
More sources

Conference papers on the topic "45.8 to 50(Category III)"

1

Kaur, Inderjit, Swarupa Mitra, Manoj Kumar Sharma, et al. "Case report of vaginal melanoma." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685371.

Full text
Abstract:
Primary malignant melanoma of vagina is a rare disease with a predilection for local recurrence, distant metastasis and short survival time. Due to the low incidence and lack of reporting in the literature, treatment choices still remain controversial. We describe 2 cases of vaginal malignant melanoma. A 42 yr old female presented with complaints of post coital and per vaginal bleed of 1 month duration. Examination findings show growth 6 cm x 6 cm on anterior vaginal wall, another 3 x 3 cm lesion on right lateral vaginal wall. Vaginal biopsy showed malignant melanoma, S-100 and HMB-45 positive
APA, Harvard, Vancouver, ISO, and other styles
2

Kaur, Inderjit. "Case report of vaginal melanoma." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685370.

Full text
Abstract:
Primary malignant melanoma of vagina is a rare disease with a predilection for local recurrence, distant metastasis and short survival time. Due to the low incidence and lack of reporting in the literature, treatment choices still remain controversial. We describe 2 cases of vaginal malignant melanoma. A 42 yr old female presented with complaints of post coital and per vaginal bleed of 1 month duration. Examination findings shows growth 6 cm x 6 cm on anterior vaginal wall, another 3 x 3 cm lesion on right lateral vagianl wall. Vaginal biopsy showed malignant melanoma, S-100 and HMB-45 positiv
APA, Harvard, Vancouver, ISO, and other styles
3

Aerne, Nick, Taylor J. Rawlings, and John P. Parmigiani. "Adhesive Properties Subject to Temperature Testing for Cohesive Zone Modeling." In ASME 2017 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/imece2017-70626.

Full text
Abstract:
The growth of lightweight components and need for non-destructive fastening techniques leads to the use of adhesives in many industries. Modeling the behavior of adhesives in fastening joints can help in the design process to make an optimized joint, with minimal waste. However, in available material properties provided by manufactures of adhesives there is a gap in what is sufficient to accurately model and predict the behavior of real-world adhesive conditions. An adhesive joint may be loaded in mode I, mode II, mode III, or a combination of these in service. In components with outdoor appli
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic '45.8 to 50(Category III)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography